Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, et al. N Engl J Med 2024 Sep 9. doi: 10.1056/NEJMoa2406673.

Read + Share

Amedeo Smart

Independent Medical Education

Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med 2024 Sep 9. doi: 10.1056/NEJMoa2406673.
PMID: 39248309